EMERYVILLE, Calif., Dec. 12 /PRNewswire-FirstCall/ -- Bionovo, Inc. announced today that Isaac Cohen, the company’s chairman and chief executive officer, is scheduled to present at the New York Society of Security Analysts 9th Annual Biotech Specialty Pharma Conference on Wednesday December 14, at 1:40 p.m. The conference will be held at The Harvard Club, 27 West 44th Street, NYC.
Bionovo, Inc.
Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women’s health. The company has two drugs ready to enter Phase 2 clinical testing, one for breast cancer therapy and another to treat conditions associated with menopause. The company is developing its products in close collaboration with leading U.S. academic research centers including the University of California, San Francisco; University of Colorado Health Sciences Center; University of California, Berkeley; and University of Texas, Southwestern. For further information please visit: www.bionovo.com.
Forward-looking Statements
This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as “believes,” “expects,” or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third-party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated, or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission SEC), which are available at www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
Bionovo, Inc.
CONTACT: Jim Stapleton, Chief Financial Officer of Bionovo, Inc.,+1-510-601-2000, or jim@bionovo.com; or Carolyn Bumgardner Wang ofWeissComm Partners, +1-415-946-1065, or carolyn@weisscommpartners.com, forBionovo, Inc.
Web site: http://www.bionovo.com//
